Virtual Library
Start Your Search
Xiangyi Ma
Author of
-
+
P17 - Locoregional and Oligometastatic Disease - Biomarkers (ID 127)
- Event: WCLC 2020
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P17.03 - Lung Adenocarcinoma with Lymph Node Metastasis: Is Ground Glass Opacity Component a Prognostic Factor? (ID 3598)
00:00 - 00:00 | Presenting Author(s): Xiangyi Ma
- Abstract
Introduction
Ground glass opacity (GGO) component is usually associated with better prognosis in early-stage lung adenocarcinoma. However, the prognostic impact of GGO component in lung adenocarcinoma with lymph node metastasis remains unclear.
Methods
A total of 669 patients with N1/N2 M0 lung adenocarcinoma receiving complete resection and systemic lymph node resection from 2008 to 2015 were reviewed, including 603 solid and 66 part-solid lesions. Propensity score matching (PSM) analysis and Cox regression were performed to determine whether GGO component was an indipendent prognostic factor. Recurrence-free survival (RFS) and overall survival (OS) were plotted using Kaplan Meier method, and compared using Logrank test.
Results
After 1:1 PSM, 58 patients were selected from both part-solid and solid groups. OS and RFS curves showed no significant difference between two groups (RFS: p=0.6470, OS: p=0.2479). Multivariate Cox regression analysis confirmed that GGO component was not an independent prognostic factor toward RFS [hazard ratio (HR): 1.195(0.852-1.677), P=0.304] or OS [HR: 1.294(0.898-1.866), P=0.167]. The median consolidation/tumor ratio (CTR) of 66 part-solid lesions was 0.84 (range: 0.64-0.97). Among 66 part-solid lesions, no significant difference was found in prognosis of CTR < or ≥ 80% subgroups (RFS: p=0.3006, OS: p=0.9364, respectively). Multivariate Cox regression confirmed that CTR was not a significant prognostic factor in the part-solid group.
Table 1 Baseline characteristics for patients with solid/part-solid nodules on CT before and after PSM Characteristics
Before PSM
P
After PSM
P
Solid
Part-solid
Solid
Part-solid
n=603
n=66
n=58
n=58
Male sex
316(52.4)
21(31.8)
0.002
18(31)
19(32.8)
1.000
Age
<65
431(71.5)
36(54.5)
0.007
32(55.2)
31(53.4)
1.000
≥65
172(28.5)
30(45.5)
26(44.8)
27(46.6)
Smoking history
Never
380(63)
50(75.8)
0.043
45(77.6)
44(75.9)
1.000
Former/present
223(37)
16(24.2)
13(22.4)
14(24.1)
Surgery mode
Lobectomy
528(87.6)
63(95.5)
0.327
54(93.1)
55(94.8)
1.000
Bilobectomy
46(7.6)
3(4.5)
2(3.4)
3(5.2)
Pneumonectomy
23(3.8)
0(0)
0(0)
0(0)
Sleeve lobectomy
6(1)
0(0)
0(0)
0(0)
Tumor size, cm
3(2.4-4)
2.5(2-3.5)
0.008
2.5(2.3-3.3)
2.6(2.1-3.5)
0.863
Pathological subtype
LPA/APA/PPA
395(65.5)
58(87.9)
<0.001
51(87.9)
50(86.2)
1.000
MPA/SPA/IMA
208(34.5)
8(12.1)
7(12.1)
8(13.8)
pT
T1a
6(1)
0(0)
0.011
0(0)
0(0)
1.000
T1b
86(14.3)
14(21.2)
10(17.2)
10(17.2)
T1c
133(22.1)
21(31.8)
20(34.5)
20(34.5)
T2a
241(40)
27(40.9)
26(44.8)
25(43.1)
T2b
57(9.5)
4(6.1)
2(3.4)
3(5.2)
T3
63(10.4)
0(0)
0(0)
0(0)
T4
17(2.8)
0(0)
0(0)
0(0)
pN
N1
175(29)
29(43.9)
0.016
23(39.7)
24(41.4)
1.000
N2
428(71)
37(56.1)
35(60.3)
34(58.6)
Stage
IIB
151(25)
29(43.9)
<0.001
23(39.7)
24(41.4)
1.000
IIIA
396(65.7)
37(56.1)
35(60.3)
34(58.6)
IIIB
56(9.3)
0(0)
0(0)
0(0)
Lymph node resected, n
20(15-26)
16.5(12.3-24.8)
0.04
18(13-23)
17.5(13-23.8)
0.890
Positive lymph nodes, n
3(1-7)
2.5(1-4.8)
0.131
2(1.3-4)
2(1-4)
0.813
Adjuvant chemotherapy
507(84.1)
57(86.4)
0.724
49(84.5)
50(86.2)
1.000
Abbreviations: PSM, propensity-score matching; IQR, interquartile range; LPA, lepidic predominant adenocarcinoma; APA, acinar predominant adenocarcinoma; PPA, papillary predominant adenocarcinoma; MPA, micro-papillary predominant adenocarcinoma; SPA, solid predominant adenocarcinoma; IMA, invasive mucous adenocarcinoma.
Conclusion
Ground glass opacity component does not predict better prognosis in patients with pathological N1/N2 M0 lung adenocarcinoma.
